[theold]

The UK has adopted the world’s first subscription payment model for two new antibiotics. The National Health Service will pay Pfizer and Shionogi up to £10 million a year for ten years for them, regardless of how many doses are administered to patients.

‘It is a good start, provided other nations follow suit,’ he adds, but also represents an important signal to the market.

Garner believes this can be part of the solution, but he also views positively the rewarding of patent extensions to antibiotic developers on existing blockbuster drugs. ‘This isn’t relying on government funding, though we all would pay for it as consumers,’ he notes.

There will ‘probably be different approaches, in different parts of the globe,’ predicts Garner, ‘but in the end all of them could provide the funds for pharmaceutical companies to restart their antibiotic drug development programmes.’


https://www.chemistryworld.com/news/uk-t...55.article